- Home
- HCVI vs MDWD Comparison
HCVI vs MDWD Comparison
Compare HCVI & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCVI
- MDWD
- Stock Information
- Founded
- HCVI 2021
- MDWD 2000
- Country
- HCVI United States
- MDWD Israel
- Employees
- HCVI N/A
- MDWD N/A
- Industry
- HCVI Blank Checks
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- HCVI Finance
- MDWD Health Care
- Exchange
- HCVI Nasdaq
- MDWD Nasdaq
- Market Cap
- HCVI 176.6M
- MDWD 179.1M
- IPO Year
- HCVI 2021
- MDWD 2014
- Fundamental
- Price
- HCVI $10.62
- MDWD $16.80
- Analyst Decision
- HCVI
- MDWD Strong Buy
- Analyst Count
- HCVI 0
- MDWD 1
- Target Price
- HCVI N/A
- MDWD $28.00
- AVG Volume (30 Days)
- HCVI 24.6K
- MDWD 64.7K
- Earning Date
- HCVI 01-01-0001
- MDWD 08-14-2024
- Dividend Yield
- HCVI N/A
- MDWD N/A
- EPS Growth
- HCVI N/A
- MDWD N/A
- EPS
- HCVI N/A
- MDWD N/A
- Revenue
- HCVI N/A
- MDWD $20,141,000.00
- Revenue This Year
- HCVI N/A
- MDWD $30.16
- Revenue Next Year
- HCVI N/A
- MDWD $18.44
- P/E Ratio
- HCVI N/A
- MDWD N/A
- Revenue Growth
- HCVI N/A
- MDWD N/A
- 52 Week Low
- HCVI $10.30
- MDWD $7.26
- 52 Week High
- HCVI $11.47
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- HCVI 49.55
- MDWD 41.82
- Support Level
- HCVI $10.62
- MDWD $16.85
- Resistance Level
- HCVI $10.66
- MDWD $17.48
- Average True Range (ATR)
- HCVI 0.01
- MDWD 1.03
- MACD
- HCVI -0.00
- MDWD -0.24
- Stochastic Oscillator
- HCVI 33.33
- MDWD 12.79
About HCVI Hennessy Capital Investment Corp. VI
Hennessy Capital Investment Corp VI is a shell company.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.